KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBIT: 2010-2025

Historic EBIT for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $76.5 million.

  • Emergent BioSolutions' EBIT rose 18.60% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 182.87%. This contributed to the annual value of -$108.7 million for FY2024, which is 85.04% up from last year.
  • Per Emergent BioSolutions' latest filing, its EBIT stood at $76.5 million for Q3 2025, which was up 4,681.25% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' EBIT registered a high of $286.8 million during Q4 2021, and its lowest value of -$292.9 million during Q2 2023.
  • Moreover, its 3-year median value for EBIT was -$9.5 million (2024), whereas its average is -$64.3 million.
  • Its EBIT has fluctuated over the past 5 years, first spiked by 894.83% in 2021, then slumped by 2,239.13% in 2023.
  • Emergent BioSolutions' EBIT (Quarterly) stood at $286.8 million in 2021, then slumped by 119.28% to -$55.3 million in 2022, then climbed by 20.80% to -$43.8 million in 2023, then surged by 78.31% to -$9.5 million in 2024, then climbed by 18.60% to $76.5 million in 2025.
  • Its last three reported values are $76.5 million in Q3 2025, $1.6 million for Q2 2025, and $49.9 million during Q1 2025.